Hematology / Oncology CE Activities

RMEI Presentations

RMEI DECISION SUPPORT AIDS

View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RSS Latest Hematology / Oncology Articles
  • A Double Whammy on Gastric Cancer Risk March 30, 2023
    This editorial describes the science behind a study of determinants of gastric cancer risk — in particular, an interaction between genetic variants in a specific class of genes and infection with Helicobacter pylori.
    Anne Müller, Jiazhuo He
  • Helicobacter pylori, Homologous-Recombination Genes, and Gastric Cancer March 30, 2023
    Infection with Helicobacter pylori is known to confer a risk of gastric cancer. In this study, persons who carried certain genetic variants and were infected with H. pylori had an excess risk of gastric cancer.
    Yoshiaki Usui, Yukari Taniyama, Mikiko Endo, Yuriko N. Koyanagi, Yumiko Kasugai, Isao Oze, Hidemi Ito, Issei Imoto, Tsutomu Tanaka, Masahiro Tajika, Yasumasa Niwa, Yusuke Iwasaki, Tomomi Aoi, Nozomi Hakozaki, Sadaaki Takata, Kunihiko Suzuki, Chikashi Terao, Masanori Hatakeyama, Makoto Hirata, Kokichi Sugano, Teruhiko Yoshida, Yoichiro Kamatani, Hidewaki Nakagawa, Koichi Matsuda, Yoshinori Murakami, Amanda B. Spurdle, Keitaro Matsuo, Yukihide Momozawa
  • Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer March 27, 2023
    A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo.
    Mansoor R. Mirza, Dana M. Chase, Brian M. Slomovitz, René dePont Christensen, Zoltán Novák, Destin Black, Lucy Gilbert, Sudarshan Sharma, Giorgio Valabrega, Lisa M. Landrum, Lars C. Hanker, Ashley Stuckey, Ingrid Boere, Michael A. Gold, Annika Auranen, Bhavana Pothuri, David Cibula, Carolyn McCourt, Francesco Raspagliesi, Mark S. Shahin, Sarah E. Gill, Bradley J. Monk, Joseph Buscema, Thomas J. Herzog, Larry J. Copeland, Min Tian, Zangdong He, Shadi Stevens, Eleftherios Zografos, Robert L. Coleman, Matthew A. Powell, the RUBY Investigators

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.

Previously Published CE Activities